Turpaz Industries (TRPZ) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
3 Nov, 2026Executive summary
H1 2025 sales reached $123.777M, up 44.3% YoY, with 11.6% organic growth; acquisitions and synergies also contributed.
Q2 sales reached a record $63.418M, up 35.6% YoY, with 14.2% organic growth.
H1 adjusted EBITDA was $28.253M, up 54.4%, at a 22.8% margin; net income was $10.633M, up 57.7%.
Financial highlights
Q2 gross profit rose 36.7% to $24.715M, with a 39.0% margin; operating income rose 67.9% to $9.922M.
Q2 adjusted EBITDA increased 47.5% to $14.638M, with a 23.1% margin; reported EBITDA was $14.3M.
Q2 net income rose 52.1% to $5.223M, or 8.2% of sales; non-GAAP net income was $7.5M, or 11.8% of sales.
H1 gross profit rose 48.5% to $48.234M; operating income increased 72.1% to $19.556M, or 15.8% of sales.
H1 cash flow from operations was $13.134M, versus $11.254M in H1 2024.
Outlook and guidance
Q3 sales pace implied a forward-looking annual run rate of ~$300M, including the full impact of Carotex and Attractive Scent and expected growth; actual results may vary.
Specialty Fine Ingredients improvement was expected to continue in 2025, with higher-value products supporting profitability in coming quarters; further interest-rate cuts were expected to benefit finance expenses.
A strong global acquisitions pipeline was cited as part of the expansion strategy.
Latest events from Turpaz Industries
- Record Q1 growth was led by Taste and acquisitions, while Specialty Fine Ingredients weakened.TRPZ
Q1 2024 - Acquisitions and Taste/Scent growth lifted record results despite Specialty Fine Ingredients weakness.TRPZ
Q2 2024 - Acquisition-led growth lifted sales and adjusted EBITDA as Specialty Fine Ingredients weakened.TRPZ
Q3 2024 - FY24 sales rose 48.4%, with adjusted EBITDA up 54.8%.TRPZ
Q4 2024 - Record Q1 sales of $60.4M and adjusted EBITDA of $13.6M reflected organic growth and acquisitions.TRPZ
Q1 2025 - Q3 sales rose 57.4% as organic growth and acquisitions lifted adjusted EBITDA 55.1%.TRPZ
Q3 2025 - Revenue rose 45.6% in 2025 as adjusted EBITDA margin reached 23.1%.TRPZ
Q4 2025 - Q1 revenue rose 38.6%; Phoenix and Romessence lifted the sales run rate to $380m.TRPZ
Q1 2026 - Acquisitions and organic growth drove record sales, while integration and production ramp-up shape the outlook.TRPZ
Q2 2026